Monitoring programmed death 1 receptor and its ligand on circulating tumor-associated cells in recurrent or metastatic non–small-cell lung cancer predicts response to immunotherapy and radiation.

A new analysis of real-world data show that just as in solid tumors, higher tumor mutational burden (TMB) and PD-L1 expression in blood cancers are linked to less-optimistic prognoses.

A first-in-class peptide-based PET tracer, 18F-AlF-NOTA-PCP2, can effectively measure PD-L1 expression in patients with head and neck cancers, outperforming the conventional tracer 18F-FDG. 18F ...

Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of Head and Neck Patients.

Key Takeaways Leronlimab increases PD-L1 expression on circulating tumor cells, potentially converting "cold" tumors to "hot" ones, enhancing immune response in metastatic triple-negative breast ...